Literature DB >> 24265196

The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?

Marcelo G Bonini1, Benjamin N Gantner.   

Abstract

AMP-activated kinase (AMPK) is a central cellular energetic biosensor and regulator of a broad array of cellular metabolic routes activated by nutrient deprivation, mitochondrial dysfunction, oxidative stress, and cytokines. The activation of AMPK maintains ATP levels in response to hypoxia, mitochondrial dysfunction, and shortage of essential metabolic fuels. Activated AMPK turns on energy sparing pathways and promotes antiapoptotic functions thereby permitting cells to survive extremely hostile conditions for prolonged periods of time. Cancer cells in solid tumors are generally subjected to such harsh conditions; however, they manage to efficiently survive and proliferate. This is likely due, in great part, to a peculiar form of metabolism that is heavily reliant on glycolysis and which promotes cancer cell adaptation and tumor progression. AMPK controls the influx and utilization of glucose by cancer cells and therefore has emerged as an attractive target to treat cancer. Investigations exploring this possibility demonstrated that activators or inhibitors of AMPK impact cancer cell viability and possibly cancer progression. For example, the AMPK activator metformin induces apoptosis in a variety of cancer cell lines and models. A major problem with many of the studies on metformin is that little effort has been invested in unraveling how metformin activates AMPK in the many contexts it has been tested. This is significant because many AMPK-independent effects of metformin have been documented. The notion that AMPK acts solely as a tumor suppressor also conflicts with findings that it confers resistance to nutrient deprivation, sustains NADPH levels in cancer cells, facilitates stress-induced gene transcription, promotes cell survival via antiapoptotic function upregulation, intermediates epithelial-to-mesenchymal transition, and increases malignant transformation. These are all recognized steps necessary for the successful evolution of tumors. This review highlights some of these findings and proposes that the role of AMPK in cancer should be reconsidered in light of the complex roles of AMPK under different metabolic conditions.
© 2012 IUBMB.

Entities:  

Keywords:  AMPK; complex diseases; metformin; nutrient deprivation; signaling; stress-activated signaling

Mesh:

Substances:

Year:  2013        PMID: 24265196     DOI: 10.1002/iub.1213

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  22 in total

Review 1.  Crosstalk between calcium and reactive oxygen species signaling in cancer.

Authors:  Nadine Hempel; Mohamed Trebak
Journal:  Cell Calcium       Date:  2017-01-18       Impact factor: 6.817

2.  Distinct Effects of miR-210 Reduction on Neurogenesis: Increased Neuronal Survival of Inflammation But Reduced Proliferation Associated with Mitochondrial Enhancement.

Authors:  Ludmila A Voloboueva; Xiaoyun Sun; Lijun Xu; Yi-Bing Ouyang; Rona G Giffard
Journal:  J Neurosci       Date:  2017-02-10       Impact factor: 6.167

Review 3.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Authors:  Ayesha S Khan; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2017-02-01       Impact factor: 14.432

4.  A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.

Authors:  Robert L Plews; Adlina Mohd Yusof; Chaojie Wang; Motoyasu Saji; Xiaoli Zhang; Ching-Shih Chen; Matthew D Ringel; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2015-02-24       Impact factor: 5.958

5.  Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma.

Authors:  Janki M Desai; Aniruddha S Karve; Gary A Gudelsky; Mruniya V Gawali; William Seibel; Larry Sallans; Biplab DasGupta; Pankaj B Desai
Journal:  Invest New Drugs       Date:  2022-07-08       Impact factor: 3.651

6.  Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma.

Authors:  Deeba N Syed; Rahul K Lall; Jean Christopher Chamcheu; Omar Haidar; Hasan Mukhtar
Journal:  Arch Biochem Biophys       Date:  2014-07-09       Impact factor: 4.013

7.  8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.

Authors:  Alper Y Kearney; You-Hong Fan; Uma Giri; Babita Saigal; Varsha Gandhi; John V Heymach; Amado J Zurita
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

8.  Antifatigue Activity of Liquid Cultured Tricholoma matsutake Mycelium Partially via Regulation of Antioxidant Pathway in Mouse.

Authors:  Quan Li; Yanzhen Wang; Guangsheng Cai; Fange Kong; Xiaohan Wang; Yang Liu; Chuanbin Yang; Di Wang; Lirong Teng
Journal:  Biomed Res Int       Date:  2015-11-30       Impact factor: 3.411

9.  Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.

Authors:  M A Babcook; R M Sramkoski; H Fujioka; F Daneshgari; A Almasan; S Shukla; R R Nanavaty; S Gupta
Journal:  Cell Death Dis       Date:  2014-11-20       Impact factor: 8.469

10.  AMP-activated protein kinase is dispensable for maintaining ATP levels and for survival following inhibition of glycolysis, but promotes tumour engraftment of Ras-transformed fibroblasts.

Authors:  Joffrey Pelletier; Danièle Roux; Benoit Viollet; Nathalie M Mazure; Jacques Pouysségur
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.